News - Page 67 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Psychedelics Take a Step Towards the Policy Agenda in Czechia

Psychedelics Take a Step Towards the Policy Agenda in Czechia

Post published:February 21, 2023
Post category:2022 Year in Review

Read more about the article The Medical Potential of Psychedelics: A View from the European Union

The Medical Potential of Psychedelics: A View from the European Union

Post published:February 21, 2023
Post category:2022 Year in Review

Read more about the article Psychedelic Bulletin #131: Study Turns Understanding of Psychedelic-Induced Neuroplasticity Inside Out; EU Regulators Show Interest in Psychedelics; What Next for At-Home Ketamine Therapy?

Psychedelic Bulletin #131: Study Turns Understanding of Psychedelic-Induced Neuroplasticity Inside Out; EU Regulators Show Interest in Psychedelics; What Next for At-Home Ketamine Therapy?

Post published:February 20, 2023
Post category:Psychedelic Bulletin

Read more about the article Numinus Expands Research Capabilities with new Phoenix Clinical Research Site

Numinus Expands Research Capabilities with new Phoenix Clinical Research Site

Post published:February 17, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Non-Executive Director Appointment

Bright Minds Biosciences Announces Non-Executive Director Appointment

Post published:February 17, 2023
Post category:Press Release

Read more about the article Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

Post published:February 16, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

Post published:February 16, 2023
Post category:Press Release

Read more about the article Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

Post published:February 16, 2023
Post category:Press Release

Read more about the article First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028

First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028

Post published:February 15, 2023
Post category:Press Release

Read more about the article Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US

Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US

Post published:February 15, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.